AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04000126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100ml 0,9% NaCl iv 10min before intubation
Study NCT04000126 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral Index (BIS)
Description: Bispectral Index will be monitored to assess the depth of anaesthesia
Study NCT04000126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS)
Description: Bispectral Index will be monitored to assess the depth of anaesthesia
Study NCT04000126 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bispectral Index (BIS)
Description: Bispectral Index will be monitored to assess the depth of anaesthesia
Study NCT04000126 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HR
Description: HR in beats/min will be measured by the electrocardiogram monitor
Study NCT04000126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HR
Description: HR in beats/min will be measured by the electrocardiogram monitor
Study NCT04000126 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HR
Description: HR in beats/min will be measured by the electrocardiogram monitor
Study NCT04000126 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BP
Description: BP will be measured automatically by an occluding upper arm cuff
Study NCT04000126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BP
Description: BP will be measured automatically by an occluding upper arm cuff
Study NCT04000126 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: BP
Description: BP will be measured automatically by an occluding upper arm cuff
Study NCT02106351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Subjects randomised to receive Dysport 2 U/kg, 8 U/kg or 16 U/kg administered intramuscularly in the study limb.
Study NCT01972412 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: telephone support
Description: Telephone support for four months about healthy diet, physical activity and medication use.
Study NCT00726180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab (Herceptin®)
Description: About 1 week (4 - 7 days) before scheduled breast surgery, consisting of lumpectomy or mastectomy, subjects will receive a dose of trastuzumab (Herceptin®). Trastuzumab will be given through an IV or port for approximately 90 minutes. During this time, subjects will be closely monitored by a chemotherapy nurse to make sure that subjects do not have a reaction to the medication. It is possible that the infusion of the medication will need to be slowed down, in which case, the time for the infusion will be longer than 90 minutes. The one dose of the trastuzumab drug will be provided by the study (not billed to insurance), but the charges to administer the drug will be billed to subjects or subjects health insurance.
Study NCT02536105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate HCl ER tablets 1
Study NCT02536105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02536105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate HCl ER tablets 2
Study NCT02536105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate HCl ER for suspension
Study NCT04406714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trial Mailed FIT Intervention - Age Group 50-75
Description: Subjects are mailed an introductory letter advising them that they will receive a FIT kit in the mail. Next, subjects are mailed a FIT packet in an envelope that contains a cover letter, CRC information sheet, FIT instruction sheet, and FIT kit with a pre-paid return envelope. Subjects receive up to two mailed letters reminding them to complete and return the FIT. Subjects receive FIT results via letter or phone call.
Study NCT04406714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sub-Study Mailed FIT Intervention Enhanced Envelope - Age Group 45-49
Description: Subjects are mailed an introductory letter advising them that they will receive a FIT kit in the mail. Next, subjects are mailed a FIT packet in an enhanced envelope that contains a cover letter, CRC information sheet, FIT instruction sheet, and FIT kit with a pre-paid return envelope. The enhanced envelope is a yellow padded envelope with a USPS tracking label and sticker message: Important information from your doctor. Subjects receive up to two mailed letters reminding them to complete and return the FIT. Subjects receive FIT results via letter or phone call.
Study NCT04406714 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sub-Study Mailed FIT Active Comparator Plain Envelope - Age Group 45-49
Description: Subjects are mailed an introductory letter advising them that they will receive a FIT kit in the mail. Next, subjects are mailed a FIT packet in plain envelope that contains a cover letter, CRC information sheet, FIT instruction sheet, and FIT kit with a pre-paid return envelope. The plain envelope is a white envelope without a USPS tracking label or sticker message. Subjects receive up to two mailed letters reminding them to complete and return the FIT. Subjects receive FIT results via letter or phone call.
Study NCT01787006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Initial doses 400mg/m2 (day 1), followed by weekly doses of 250mg/m2 for 14 weeks in total
Study NCT01787006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, 5-FU
Description: 5-FU: 1000mg/m2 per day as continuous infusion on day 1-4 of cycle 1 and 2, 750mg/m2/day as continuous infusion on day 1-4 of cycle 3 and 4~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle
Study NCT01787006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin, 5-FU
Description: 5-FU: 1000mg/m2 per day as continuous infusion on day 1-4 of cycle 1 and 2, 750mg/m2/day as continuous infusion on day 1-4 of cycle 3 and 4~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle
Study NCT01787006 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery.
Study NCT01787006 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery.
Study NCT02081378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib (ABL001)
Description: Asciminib was be administered orally in a dose escalation schedule.
Study NCT02081378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Asciminib and Nilotinib was administered orally in CML patients
Study NCT02081378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Asciminib and imatinib was administered orally in CML patients
Study NCT02081378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Asciminib and dasatinib was administered orally in CML patients
Study NCT01944436 — intervention group
Intervention type: DRUG
Intervention: Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)
Study NCT05452915 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological (NPA)
Description: The neuropsychological assessment consists of following tests and questionnaires:~* Wechsler Adult Intelligence Scale (WAIS)-III: Digit-Symbol-Coding (Coding)~* WAIS-IV: Digit Span, Matrix reasoning~* Delis-Kaplan Executive Function Scale (D-KEFS): Color-Word Test, Word Fluency Test~* Ruff 2 \& 7~* MapCog Spectra~Questionnaires:~* EuroQoL five dimensions questionnaire (EQ5D)~* Hospital Anxiety and Depression Scale (HADS)~* Insomnia Severity Index (ISI)~* Multidimensional Fatigue Inventory-20 (MFI-20)~* Multidimensional Pain Inventory (MPI)~* Screening questions on physical activity~* Visual analogue scale on fatigue (VAS-f) before and after NPA~* Visual analogue scale on fatigue (VAS-f) and pain before and after the fMRI scanning.~* Pain level, experienced during the NPA, will be rated (0-10) at the end of the session
Study NCT05452915 — intervention group
Intervention type: OTHER
Intervention: Imaging
Description: Imaging (24 patients + 22 controls):~BOLD resting-state before and after 20-min vigilance task (e-prime). During the vigilance task, fMRI is performed.~Clinical protocol:~1. High-resolution T1-weighted.~2. High-resolution T2-weighted Scan (FLAIR).
Study NCT05452915 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory biomarkers
Description: Blood samples from inflammatory biomarkers will be taken on 36 patients and 36 controls. Everyone who undergoes imaging will undergo blood tests.
Study NCT04881214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: pulmonary rehabilitation for 12 weeks, 3 times a week. control will take place at 3, 6 and 12 months
Study NCT04001556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Minor Salivary gland Biopsy
Description: Minor salivary gland biopsy with injection of lidocain
Study NCT04001556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ARFI
Description: Acoustic Radiation Force Impulse on Major Salivary Glands
Study NCT04001556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MSG US
Description: Ultrasonography of Major Salivary Glands
Study NCT01897051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin + propranolol
Description: 1. Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)~2. Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.~(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).~If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared.
Study NCT01897051 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol + Placebo
Description: 1. Placebo of Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)~2. Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.~(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).~If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared.
Study NCT04090346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: Fecal Microbiota Transplant (FMT) is a procedure to replace beneficial bacteria which has been killed or suppressed in the colon.
Study NCT02300870 — intervention group
Intervention type: DRUG
Intervention: Optison
Description: Echocardiogram with IV contrast
Study NCT02105194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: total body exposure to greater than atmospheric pressure oxygen
Study NCT01326247 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: thermal waters nasal irrigation
Description: The first group (group 1) has practiced crenotherapy with hyper-mineral chloride sodium water aerosol by nasal adapter for 15 days per month, for three consecutive months, at thermal spa services of Lacco Ameno, while the control group (group 2) was treated, in the same period, daily, by a micronized nasal douche with 0.9% NaCl (isotonic) solution.
Study NCT02141191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled hypertonic saline (7%)
Description: Inhaled hypertonic saline delivered by nasal cannula using the Parion transnasal Pulmonary Aerosol Delivery (tPAD) device
Study NCT04478162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supporting parents who have premature babies to be ready for discharge with the training given within the scope of FICare model.
Description: At least 1 week of FICare training for parents At least 4 hours of training on FICare for health professionals Trainings will be held between 13:30 and 15:30 in a training room with heat, light and seating arrangement (for parents who are not able to participate in the training during the week, trainings will be held at the appropriate time interval on the weekend .) Premature baby dummy on oral care, eye care, nose care, ear care, skin care, bath, attired in clothes,/removal, safe sleeping baby, safe transport, kangaroo care (physical contact), non-invasive drug application will be shown and the parents also will be asked to implement,
Study NCT02797028 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anthocyanidins capsule
Description: Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
Study NCT02797028 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
Study NCT02797028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
Study NCT02864407 — intervention group
Intervention type: DRUG
Intervention: Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)
Description: The recommended dose for adults is 5 microgram Tiotropium and 5 microgram Olodaterol given as two puffs from the Respimat® inhaler once daily at the same time of the day.
Study NCT03156257 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood volume collected specifically for this study
Description: The subject will be sitting in a chair, and a needle will be inserted into a vein in their arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
Study NCT03162185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Experimental group participants (n = 30) will receive 20 mg of Escitalopram for 7 days.
Study NCT03162185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group participants (n = 30) will receive a placebo for 7 days.
Study NCT01540513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM404
Description: injection of 5.0mCi I-124 NM404 Arms: I124-NM404 brain metastases or GBM imaging~Other Names:~PET imaging with I-124 NM404
Study NCT01540513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM404
Description: injection of an experimental imaging agent, 5mCi I-124NM404
Study NCT01766908 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clamp cord 20, 40 or 60 seconds following vaginal or cesarean delivery
Description: None to add
Study NCT01236040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational vaccine GSK2590066A
Description: Intramuscular injection, two doses
Study NCT01236040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational vaccine GSK2592984A
Description: Intramuscular injection, two doses
Study NCT01236040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational vaccine GSK2340274A
Description: Intramuscular injection, two doses
Study NCT01236040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational vaccine GSK2340273A
Description: Intramuscular injection, two doses
Study NCT01236040 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection, two doses
Study NCT01720316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycine
Description: Double-blind placebo controlled trial of glycine or placebo, followed by open-label glycine
Study NCT01720316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00753129 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone position with head elevation
Description: Head elevation of 30° in prone position (Ant-Trendelenburg position of the whole bed)
Study NCT02824627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: A growing body of data shows that intra-nasal administration of oxytocin has promise for treating a host of psychiatric disorders. Considerable data indicates that oxytocin reduces amygdala response to negative stimuli in patients with generalized anxiety disorder, borderline personality disorder, and post-traumatic stress disorder. Given that one of the potential underlying neurobiological mechanisms of irritability and emotional dysregulation in pediatric population with disruptive behavior and mood disorder is the hyperactivity of amygdala to negative emotional stimuli, and that oxytocin reduces this, it is critical to determine the extent to which this intervention improves irritability and emotional dysregulation in children and adolescents with disruptive behavior and mood disorders.
Study NCT02824627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive substance administered in volume equivalent to volume administered in active treatment arm.
Study NCT02895347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surgical Simulation Practice Modules
Description: The surgical simulation practice modules simulate surgical settings for suturing.
Study NCT04855214 — intervention group
Intervention type: OTHER
Intervention: Qualitative Analysis
Description: Mixed methods analysis of the user's experience with upper limb prosthetics.
Study NCT03452956 — intervention group
Intervention type: OTHER
Intervention: None-Observation Only
Description: No intervention-this is an observational study
Study NCT03950453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Mindfully for Health Nutrition (PMH)
Description: PMH will include included the following components:~1. mindfulness strategies as outlined in the MBSR manual,~2. mindful parenting concepts,~3. mindful eating and awareness of family choices;~4. self and child monitoring of food intake, PA and emotional reactivity;~5. utilizing mindfulness for emotion regulation and distress tolerance,~6. behavioral strategies of goal setting and implementing increasing frequency of healthy food intake and physical activity (PA)
Study NCT03950453 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contact Control Nutrition (C+N)
Description: Contact Control Group where parents engage in a quiet, relaxing, but stimulating activity and also nutrition counseling.
Study NCT03950453 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-randomized historical control (WLC) assessment only
Description: Non-randomized, historical control group with only assessments during intervention and follow-up period.
Study NCT06517433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: upifitamab rilsodotin
Description: XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536
Study NCT04990193 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy Protocol
Description: The conventional physical therapy protocol was designed to improve axial stability and trunk steadiness during standing and walking. The conventional therapeutic protocol for every child was 3 sessions/week for 12 consecutive weeks. Every treatment session was conducted for 2 hours with a 15-minutes rest between the two training hours.
Study NCT04990193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy Protocol
Description: The conventional physical therapy protocol was designed to improve axial stability and trunk steadiness during standing and walking. The conventional therapeutic protocol for every child was 3 sessions/week for 12 consecutive weeks. Every treatment session was conducted for 2 hours with a 15-minutes rest between the two training hours.
Study NCT04990193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraTog orthotic undergarment with its strapping system
Description: TheraTog orthotic undergarment with its strapping system was applied for eight hours every day for twelve consecutive weeks.
Study NCT02606240 — intervention group
Intervention type: DEVICE
Intervention: CO2 removal with PRISMALUNG in ARDS
Description: Observational study of patients with mild to moderate Acute Respiratory Distress Syndrome (ARDS) submitted to Extracorporeal CO2 removal (ECCO2R) with the PRISMALUNG device to allow ultraprotective mechanical ventilation with tidal volume reduction (from 6 to 4 ml/kg, predicted body weight) and plateau pressure reduction from 28-30 to 23-25 cmH2O.
Study NCT03237897 — intervention group
Intervention type: BEHAVIORAL
Intervention: Preoperative education class
Description: The preoperative enhanced recovery after surgery education class will be offered twice a week in coordination with anesthesia preoperative appointments to minimize inconvenience for patients. Patients will need to attend only one class. All participants will be offered the class. This class will be one hour in duration and will be taught by a surgical advanced care practitioner familiar with the details of colorectal surgery. The class will include detailed information about preoperative care, intraoperative care, and postoperative care.